Evidence map›Paper›PMID 36358621›Full record

ArticleCancers2022

Prognostic Value and Quantitative CT Analysis in RANKL Expression of Spinal GCTB in the Denosumab Era: A Machine Learning Approach.

Qizheng Wang, Yongye Chen, Siyuan Qin, Xiaoming Liu, Ke Liu, Peijin Xin, Weili Zhao, Huishu Yuan, Ning Lang

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 33% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Qizheng WangDepartment of Radiology, Peking University Third Hospital, Beijing 100191, China.
Yongye ChenDepartment of Radiology, Peking University Third Hospital, Beijing 100191, China.
Siyuan QinDepartment of Radiology, Peking University Third Hospital, Beijing 100191, China.
Xiaoming LiuDepartment of Research and Development, United Imaging Intelligence (Beijing) Co., Ltd., Yongteng North Road, Haidian District, Beijing 100089, China.
Ke LiuDepartment of Radiology, Peking University Third Hospital, Beijing 100191, China.
Peijin XinDepartment of Radiology, Peking University Third Hospital, Beijing 100191, China.
Weili ZhaoDepartment of Radiology, Peking University Third Hospital, Beijing 100191, China.
Huishu YuanDepartment of Radiology, Peking University Third Hospital, Beijing 100191, China.
Ning LangDepartment of Radiology, Peking University Third Hospital, Beijing 100191, China.
Peking University Third Hospital · CNPeking University · CNUnited Imaging Healthcare (China) · CN

Funding

Beijing Natural Science Foundation No. Z190020National Natural Science Foundation of China No. 81971578 and No. 81871326
6 · The paper itself

Abstract

The receptor activator of the nuclear factor kappa B ligand (RANKL) is the therapeutic target of denosumab. In this study, we evaluated whether radiomics signature and machine learning analysis can predict RANKL status in spinal giant cell tumors of bone (GCTB). This retrospective study consisted of 107 patients, including a training set (

Indexed as

giant cell tumor of boneprognosisradiomicsRANKLtomography

Identifiers

PMID36358621
PMCPMC9658803
OpenAlexW4307122274

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.